Kevin B Webster

US Patent:

6521759, Feb 18, 2003

Filed:

Apr 20, 2001

Appl. No.:

09/839751

Inventors:

Kyoung S. Kim - North Brunswick NJ
S. David Kimball - East Windsor NJ
David B. Rawlins - Morrisville PA
Raj N. Misra - Hopewell NJ
Michael A. Poss - Lawrenceville NJ
Kevin R. Webster - Yardley PA
John T. Hunt - Princeton NJ
Wen-Ching Han - Newtown PA

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D41712

US Classification:

548184

Abstract:

The present invention describes compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R , R , R , R , R , m and n are as defined in the specification. The compounds of formula I are protein kinase inhibitors and are useful in the treatment of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of Alzheimers disease, chemotherapy-induced alopecia, and cardiovascular disease.

US Patent:

20070105114, May 10, 2007

Filed:

Jul 29, 2004

Appl. No.:

10/567867

Inventors:

Martha Li - Short Hills NJ, US
Brent Rupnow - Ewing NJ, US
Kevin Webster - Hopkinton MA, US
Donald Jackson - Lawrenceville NJ, US
Tai Wong - Belle Mead NJ, US

International Classification:

C12Q 1/68
G01N 33/574

US Classification:

435006000, 435007230

Abstract:

Biomarkers having expression patterns that correlate with a response of cells to treatment with one or more cdk modulating agents, and uses thereof. Also provided are methods for testing or predicting whether a mammal will respond therapeutically to a method of treating cancer that comprises administering an agent that modulates cdk activity.

US Patent:

60403217, Mar 21, 2000

Filed:

Oct 21, 1998

Appl. No.:

9/176239

Inventors:

Kyoung S. Kim - North Brunswick NJ
S. David Kimball - East Windsor NJ
David B. Rawlins - Morrisville PA
Raj N. Misra - Hopewell NJ
Michael A. Poss - Lawrenceville NJ
Kevin R. Webster - Yardley PA
John T. Hunt - Princeton NJ
Wen-Ching Han - Newtown PA

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31425
C07D41712

US Classification:

514369

Abstract:

Compounds of the formula ##STR1## and pharmaceuticaly acceptable salts thereof. As used in formula I, and throughout the specification, the symbols have the following meanings: R. sub. 1 and R. sub. 2 are independently hydrogen, fluorine or alkyl; R. sub. 3 is aryl or heteroaryl R. sub. 4 is hydrogen, alkyl, cycloalkyl, aryl, cycloalkylalkyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl; or CO-alkyl, CONH-alkyl, COO-alkyl, SO. sub. 2 -alkyl, C(NCN)NH-alkyl, C(NNO. sub. 2)NH-alkyl, C(NH)NH-alkyl, C(NH)NHCO-alkyl, C(NOR. sub. 6)NH-alkyl, R. sub. 5 is hydrogen or alkyl; R. sub. 6 is hydrogen, alkyl, cycloalkyl, aryl, cycloalkylakyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; m is an integer of 0 to 2; and n is an integer of 1 to 3. The compounds of formula I are protein kinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis.

US Patent:

62620967, Jul 17, 2001

Filed:

Dec 15, 1999

Appl. No.:

9/464511

Inventors:

Kyoung S. Kim - North Brunswick NJ
S. David Kimball - East Windsor NJ
David B. Rawlins - Morrisville PA
Raj N. Misra - Hopewell NJ
Michael A. Poss - Lawrenceville NJ
Kevin R. Webster - Yardley PA
John T. Hunt - Princeton NJ
Wen-Ching Han - Newtown PA

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31425

US Classification:

514369

Abstract:

Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof. R. sub. 1 and R. sub. 2 are independently hydrogen, fluorine or alkyl; R. sub. 3 is aryl or heteroaryl R. sub. 4 is alkyl, cycloalkyl, aryl, cycloalkylalkyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl; m is an integer of 0 to 2; and n is an integer of 1 to 3. The compounds of formula I are protein kinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, viral diseases and fungal diseases.